Patents by Inventor Doo-Hong Park
Doo-Hong Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067535Abstract: A water purifier includes: a filter module for providing purified water by filtering raw water; a fitting valve module detachably fastened to the filter module to provide at least one of a flow path for a flow of raw water supplied to the filter module and a flow path for a flow of the purified water discharged from the filter module; and a frame including a valve support for movably supporting the fitting valve module to be movable. The fitting valve module is selectively placed in a separated state in which the fitting valve module is separated from the filter module by moving in a direction away from the filter module, or a coupled state in which the fitting valve module coupled to the filter module by moving toward the filter module.Type: ApplicationFiled: December 30, 2021Publication date: February 29, 2024Applicant: COWAY CO., LTD.Inventors: Ki Hong MIN, Man Uk PARK, Yong Yeon NOH, Dae Hwan KIM, Doo Won HAN
-
Patent number: 11524054Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.Type: GrantFiled: January 8, 2016Date of Patent: December 13, 2022Assignees: GENEXINE, INC., GREEN CROSS CORPORATIONInventors: Sang-In Yang, Jung-Won Woo, Se Hwan Yang, Young Chul Sung, Doo Hong Park, Min Woo Kim
-
Publication number: 20180264082Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.Type: ApplicationFiled: January 8, 2016Publication date: September 20, 2018Applicants: GENEXINE, INC., GREEN CROSS CORPORATIONInventors: Sang-In YANG, Jung-Won WOO, Se Hwan YANG, Young Chul SUNG, Doo Hong PARK, Min Woo KIM
-
Publication number: 20100256073Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.Type: ApplicationFiled: May 13, 2010Publication date: October 7, 2010Inventors: Eun-kyoung Lee, Ho-jeong Lee, Kong-ju Lee, Jang-seong Kim, Doo-hong Park, Yeup Yoon, Hyun-jun Kim, In-hwan Lim
-
Publication number: 20100209491Abstract: A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.Type: ApplicationFiled: May 8, 2008Publication date: August 19, 2010Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Soo In Kim, Duckhyang Shin, Hyeon Lee, Meehyein Kim, Doo-Hong Park, Yeup Yoon
-
Publication number: 20100196370Abstract: The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.Type: ApplicationFiled: November 16, 2007Publication date: August 5, 2010Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Hyun-Kyung Yu, Yeup Yoon, Jin-Hyung Ahn, In-Hwan Lim, Ho-Jeong Lee, Jang-Seong Kim, Doo-Hong Park
-
Publication number: 20090305965Abstract: Disclosed relates to a stabilized parathyroid hormone (PTH) comprising a buffer and a stabilizing agent and, more particularly, to a stabilized PTH composition in which succinic acid, malic acid, histidine or ammonium bicarbonate is used as the buffer and sorbitol or mannitol is used as the stabilizing agent. The PTH composition of the present invention can be used to formulate stably PTH protein that is much more unstable to be readily decomposed than normal low molecular weight drugs.Type: ApplicationFiled: June 5, 2006Publication date: December 10, 2009Inventors: Kwan-Yub Kang, Doo-Hong Park, Jung-Won Jeon, Yong-Seok Lee
-
Patent number: 7422874Abstract: The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human ?-globin 5? MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.Type: GrantFiled: July 27, 2001Date of Patent: September 9, 2008Assignees: Mogam Biotechnology Research Institute, Neurotech Pharmaceuticals Co., Ltd.Inventors: Jong-Mook Kim, Jung-Seob Kim, Sun-Mo Oh, Jae-Seung Yoon, Kwang-Hee Baek, Soo-Il Chung, Doo-Hong Park, Yeup Yoon
-
Patent number: 7285277Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.Type: GrantFiled: September 23, 2005Date of Patent: October 23, 2007Assignee: Mogam Biotechnology Research InstituteInventors: Jang-Seong Kim, Jin-Hyung Ahn, Hyun-Kyung Yu, Ho-Jeong Lee, Doo-Hong Park, Yeup Yoon
-
Publication number: 20070031379Abstract: The present invention relates to an anticancer or an anti-metastatic agent for gene therapy, more precisely, an anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein (a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient, and a treatment method for cancer using the same. The agent for gene therapy of the present invention has an inhibiting effect on the growth and the metastasis of a tumor, so it can be effectively used for the prevention and the treatment of various solid tumors as a metastasis inhibitor or a therapeutic agent for primary tumors.Type: ApplicationFiled: January 10, 2005Publication date: February 8, 2007Inventors: Kyu Lee, Hyunkyung Yu, Ho-Jeong Lee, Jin-Hyung Ahn, Jang-Seong Kim, Eui-Cheol Jo, Yeup Yoon, Doo-Hong Park, Seong-Tae Yun
-
Publication number: 20060013823Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.Type: ApplicationFiled: September 23, 2005Publication date: January 19, 2006Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Jang-Seong KIM, Jin-Hyung AHN, Hyun-Kyung YU, Ho-Jeong LEE, Doo-Hong PARK, Yeup YOON
-
Publication number: 20040038394Abstract: The present invention relates to a expression vector for animal cells. Specifically, the present invention relates to a expression vector, pMS vector, pSG vector and pMSG, vector, including the human &bgr;-globin 5′ MAR complementary sequence or/and the transcription termination site of gastrin gene. An expression system using the expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.Type: ApplicationFiled: August 4, 2003Publication date: February 26, 2004Inventors: Jong-Mook Kim, Jung-Seob Kim, Sun-Mo Oh, Jae-Seung Yoon, Kwang-Hee Baek, Soo-Il Chung, Doo-Hong Park, Yeup Yoon
-
Patent number: 6692735Abstract: The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.Type: GrantFiled: July 21, 1999Date of Patent: February 17, 2004Assignees: Korea Green Cross Corporation, Mogam Biotechnology Research InstituteInventors: Byoung S. Kwon, Byung S. Youn, Soo-Il Chung, Doo-Hong Park, Seung Jae Baek, Eun-Kyoung Lee, Ju-Hyung Ahn, Kong-Ju Lee
-
Patent number: 6500647Abstract: The present invention relates to a recombinant expression vector which is prepared by inserting a human parathyroid hormone gene containing a urokinase-specific cleavage site into an L-arabinose inducible vector containing a phosphoribulokinase gene fragment of Rhodabacter sphaeroides or its mutated gene as a fusion partner, or its mutate gene as a fusion partner, a recombinant microorganism transformed with the said expression vector, and a process for preparing human parathyroid hormone on a large scale by cultivating the said microorganism in a medium containing L-arabinose. In accordance with the invention, a recombinant human PTH having the same activity of the native human PTH can be prepared in a high yield through the precise control of induction by a manufacturing process which comprises a step of inducing expression of fusion protein in the microorganism transformed with the recombinant expression vector by L-arabinose.Type: GrantFiled: January 20, 2000Date of Patent: December 31, 2002Assignee: Mogam Biotechnology Research InstituteInventors: Eun-Kyung Jung, Doo-Hong Park, Soo-Il Chung